AlphaCrest Capital Management’s Viavi Solutions VIAV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-144,913
Closed -$1.89M 1098
2022
Q3
$1.89M Buy
144,913
+45,575
+46% +$649K 0.12% 254
2022
Q2
$1.31M Buy
99,338
+69,326
+231% +$998K 0.06% 536
2022
Q1
$483K Buy
30,012
+2,886
+11% +$47.6K 0.03% 911
2021
Q4
$478K Sell
27,126
-60,866
-69% -$965K 0.02% 1112
2021
Q3
$1.39M Buy
87,992
+63,474
+259% +$1.04M 0.07% 466
2021
Q2
$433K Sell
24,518
-34,357
-58% -$580K 0.02% 1005
2021
Q1
$924K Buy
58,875
+40,771
+225% +$658K 0.05% 532
2020
Q4
$271K Buy
+18,104
New +$241K 0.02% 953
2020
Q3
Sell
-13,040
Closed -$166K 1204
2020
Q2
$166K Sell
13,040
-11,632
-47% -$140K 0.03% 860
2020
Q1
$277K Sell
24,672
-49,046
-67% -$667K 0.03% 825
2019
Q4
$1.11M Sell
73,718
-50,836
-41% -$761K 0.09% 298
2019
Q3
$1.74M Buy
124,554
+85,320
+217% +$1.21M 0.11% 298
2019
Q2
$521K Buy
39,234
+16,958
+76% +$219K 0.05% 688
2019
Q1
$276K Buy
+22,276
New +$261K 0.04% 684

Other funds holding VIAV

AlphaCrest Capital Management's VIAV Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Viavi Solutions (VIAV) in Q4 2022, closing a stake of 144,913 shares — an estimated $1.89M sold.

AlphaCrest Capital Management first reported a position in VIAV in Q1 2019 and held it in 14 quarters. The position peaked at $1.89M in Q3 2022. 302 funds tracked by Wall St. Rank hold VIAV as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Viavi Solutions position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 144,913 Viavi Solutions shares in Q4 2022, an estimated $1.89M.
  • AlphaCrest Capital Management first reported a position in Viavi Solutions in Q1 2019 and held it in 14 quarters.
  • AlphaCrest Capital Management's Viavi Solutions position peaked at $1.89M in Q3 2022.
  • 302 funds tracked by Wall St. Rank held Viavi Solutions as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.